These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 19193621

  • 1. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.
    Cohen SB, Cohen MD, Cush JJ, Fleischmann RM, Mease PJ, Schiff MH, Simon LS, Weaver AL.
    J Rheumatol Suppl; 2008 Feb; 81():4-30; quiz 31-4. PubMed ID: 19193621
    [Abstract] [Full Text] [Related]

  • 2. Assessment and management of rheumatoid arthritis.
    Haraoui B.
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Unmet needs in rheumatoid arthritis.
    Bykerk V.
    J Rheumatol Suppl; 2009 Jun; 82():42-6. PubMed ID: 19509330
    [Abstract] [Full Text] [Related]

  • 6. Early rheumatoid arthritis -- is there a window of opportunity?
    Cush JJ.
    J Rheumatol Suppl; 2007 Nov; 80():1-7. PubMed ID: 17985417
    [Abstract] [Full Text] [Related]

  • 7. [Rheumatoid arthritis: milestones in classification and treatment].
    Fiehn C.
    Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
    [Abstract] [Full Text] [Related]

  • 8. Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?
    Machold KP, Nell VP, Stamm TA, Smolen JS.
    Arthritis Res Ther; 2006 Feb; 8(3):211. PubMed ID: 16719936
    [Abstract] [Full Text] [Related]

  • 9. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P.
    Methods Mol Biol; 2008 Feb; 448():413-35. PubMed ID: 18370240
    [Abstract] [Full Text] [Related]

  • 10. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 11. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P, Salaffi F, Montecucco CM, Bombardieri S, Todesco S.
    Reumatismo; 2009 Aug; 61(2):132-9. PubMed ID: 19633800
    [Abstract] [Full Text] [Related]

  • 12. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?
    Pocock JM, Vasconcelos JC, Ostör AJ.
    Rheumatology (Oxford); 2008 Jul; 47(7):1073-6. PubMed ID: 18503089
    [Abstract] [Full Text] [Related]

  • 13. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment.
    Wolfe F, Rehman Q, Lane NE, Kremer J.
    J Rheumatol; 2001 Jul; 28(7):1704-11. PubMed ID: 11469485
    [Abstract] [Full Text] [Related]

  • 14. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M.
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [Abstract] [Full Text] [Related]

  • 15. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC.
    BioDrugs; 2012 Apr 01; 26(2):65-70. PubMed ID: 22385403
    [Abstract] [Full Text] [Related]

  • 16. Innovative treatment strategies for patients with rheumatoid arthritis.
    van der Kooij SM, Allaart CF, Dijkmans BA, Breedveld FC.
    Curr Opin Rheumatol; 2008 May 01; 20(3):287-94. PubMed ID: 18388520
    [Abstract] [Full Text] [Related]

  • 17. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y.
    Korean J Intern Med; 2016 Mar 01; 31(2):210-8. PubMed ID: 26932398
    [Abstract] [Full Text] [Related]

  • 18. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.
    Arthritis Rheum; 2009 Aug 01; 60(8):2232-41. PubMed ID: 19644872
    [Abstract] [Full Text] [Related]

  • 19. Optimizing treatment with biologics.
    Mader R, Keystone E.
    J Rheumatol Suppl; 2007 Nov 01; 80():16-24. PubMed ID: 17985419
    [Abstract] [Full Text] [Related]

  • 20. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May 01; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.